Okogen Inc., a biotechnology company developing antiviral therapeutics, announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (NASDAQ: ORGS). This strategic move strengthens the company's lead ophthalmic program while establishing a foundation for expansion into additional antiviral indications. The acquisition expands Okogen's development pipeline beyond ocular infections into focused therapeutic areas including eyecare, systemic infectious disease, dermatology, and medical countermeasures for high-consequence pathogens such as filoviruses.
The company prioritizes rapid advancement of its lead ranpirnase program, OKG-0303, an investigational therapy for acute infectious conjunctivitis. This addresses a disease area where treatment remains fragmented with no single therapy addressing both viral and bacterial causes. The acquisition establishes core development pillars spanning ophthalmology, respiratory viruses, medical countermeasures for high-consequence pathogens, and dermatologic viral diseases.
Ranpirnase is a ribonuclease enzyme that disrupts viral replication inside infected cells through a host-directed mechanism. By degrading intracellular RNA involved in protein synthesis, the molecule creates a translational bottleneck that limits production of viral proteins required for viral replication. Because this mechanism targets a host process essential to viral propagation, ranpirnase represents a differentiated approach to antiviral development with the potential to reduce susceptibility to resistance observed with traditional direct-acting antivirals. Research on this mechanism has been documented in studies such as https://jamanetwork.com/journals/jama/fullarticle/1679406 and https://pubmed.ncbi.nlm.nih.gov/16769842/.
Okogen advances ranpirnase as a potential antiviral medical countermeasure and engages with U.S. and international government agencies to evaluate its role against high-consequence pathogens such as Marburg and Sudan viruses. The company is progressing parallel research in respiratory viruses including influenza and RSV. Ranpirnase has been evaluated in clinical trials involving more than 1,000 patients, generating a substantial body of safety and translational data supporting continued development.
The acquisition positions Okogen to address significant unmet medical needs across multiple therapeutic areas. In ophthalmology, the development of OKG-0303 could provide a unified treatment approach for infectious conjunctivitis, potentially simplifying clinical management. For systemic infections and medical countermeasures, ranpirnase's host-directed mechanism offers advantages against emerging pathogens where traditional antivirals face resistance challenges. The expansion into dermatologic viral diseases represents another frontier where this platform technology could prove valuable.
This strategic acquisition enables Okogen to leverage existing clinical data while accelerating development across multiple antiviral indications. The company's focus on both commercial therapeutic areas and government priority pathogens creates a diversified development strategy that addresses both immediate market needs and long-term public health challenges. The ranpirnase platform now forms the foundation for Okogen's expanded antiviral portfolio, with implications for treatment paradigms across infectious diseases.
